MedTrace Logo

A Study to Evaluate the Efficacy of ELAPR002f in Females and Males With Atrophic Acne Scars

NCT03056235 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-09-28

No results posted yet for this study

Summary

The study is designed to evaluate the efficacy of two formulations of a cross-linked tropoelastin matrix given the product codes ELAPR002f (collectively referred to as ELAPR or ELAPR002) for the treatment of rolling atrophic acne scars when administered as intradermal implants.

Conditions

  • Atrophic Acne Scar

Interventions

DEVICE

ELAPR002f

30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid

DEVICE

Saline

Saline control

Sponsors & Collaborators

  • Elastagen Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Frans Van den Berg, Doctor · Hammersmith Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-27
Primary Completion
2018-03-23
Completion
2018-09-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03056235 on ClinicalTrials.gov